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Cullin 1(CUL1), in mesothelioma cell lines and tissues.4,5
Many of these mutations affect pathways, including
the Hippo, cell cycle, mitogen-activated protein kinase
(MAPK), and wingless-type (Wnt) pathways. In addition
to somatic mutations, several fusion transcripts, such
as LATS1–presenilin 1 (PSEN1), were identiﬁed. A
downstream effect of such fusion was the inability to
suppress mesothelioma cell growth in vitro. The cell
lines and tissues originated from patients, many of
whom reported asbestos exposure (and some who did
not might have had residential exposure).
Reports in the literature thus far point toward
asbestos exposure as the predominant cause of meso-
thelioma, with susceptibility increased by genetic pre-
disposition. Whether a genetic mutation by itself is
sufﬁcient to cause mesothelioma has not been shown,
yet. With identiﬁcation of new candidate genes and
clariﬁcation of their function in the context of mesothe-
lioma, our understanding of its carcinogenesis will in-
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Malignant Mesothelioma
Using Fluorescent In Situ
HybridizationTo the Editor:
In our October 2015 letter in the Journal1 we reported
a patient with malignant mesothelioma (MM) with
ampliﬁcation of the MET gene associated with MET
receptor expression. This ﬁnding suggests that the
inhibition of MET might be used as a targeted therapy
also in selected patients with MM.2
We now report a MET copy number analysis in pa-
tients with MM scored by the Union for International
Cancer Control criteria proposed for stratiﬁcation of
non–small cell lung cancer according to the EGFR ﬂuo-
rescence in situ hybridization (FISH) assay and also
used by Go et al.3 for the scoring of MET. MET status was
classiﬁed as FISH-positive and -negative according to the
frequency of MM cells with speciﬁc copy numbers of the
MET gene and chromosome 7 centromere (CEP7).3This study was approved by the Liguria Region Ethics
Committee, and written informed consent was obtained
from all patients.
We analyzed 60 patients with MM (male, 66.7%;
median age, 60.0 years [range, 5–85 years]), including
patients with epithelioid (n ¼ 36), sarcomatoid (n ¼ 12),
biphasic (n ¼ 8), desmoplastic (n ¼ 2), and papillary
(n ¼ 2) subtypes. Thirty cases of MM were from a tissue
microarray (MS801; US Biomax Inc, Rockville, MD), 12
cases of formalin-ﬁxed parafﬁn-embedded tissues were
from the Unit of Pathology, IRCCS A.O.U. San Martino–
IST (Genova, Italy), and 18 cases were from the Division
of Histopathology (ASL5, La Spezia, Italy).
We found 5 FISH-positive cases (8.3%), of which one
epithelioid MM had MET ampliﬁcation (about 8 MET
signals on >70% of cells; MET/CEP7 ratio ¼ 4.0; Fig. 1A)
and four epithelioid MMs showed high polysomy of MET
(range of 4–10 spots of MET in about 60%–80% of MM
cells; a representative case is shown in Fig. 1D). All the
other 55 FISH-negative cases (91.7%) were disomic
for MET (a representative case is shown in Fig. 1G).
As in the previously reported case, IHC analysis
showed that ampliﬁcation was associated with moderate
expression of MET protein in cytoplasm and membrane
of MM cells (Fig. 1B). In contrast, high gene polysomy
resulted in low staining of MET protein (Fig. 1E).
In our study, we found that MET ampliﬁcation is a
rare event in patients with MM (1.7% of total cases) in
contrast to MET polysomy, which occurs more
frequently (6.7% of total cases). The biological impact
of MET polysomy on cancer cells has not been well
established. However, highly polysomic status in MM
Figure 1. Patterns of MET gene status in malignant mesothelioma (MM). The frequency of MET gene status (i.e., ampliﬁed,
polysomic, or disomic) seen in our study is indicated on the left. (A and B) One case of epithelioid mesothelioma with MET
gene ampliﬁcation and high expression of MET protein, respectively. (D and E) One case of epithelioid MM with MET gene
polysomy and low expression of MET protein, respectively. (G and H) One case of epithelioid MM with MET gene disomy and
negative expression of MET protein, respectively. (A, D, and G) Fluorescence in situ hybridization (FISH) for MET gene
(original magniﬁcation, 100). MET gene ampliﬁcation was investigated using FISH with a MET/CEP7 probe cocktail (Vysis
MET Spectrum Red FISH Probe Kit reagent/Vysis CEP 7 [D7Z1] SpectrumGreen Probe, both reagents from Abbott Molecular,
Des Plaines, IL). White arrows indicate spots of MET red signal points. (B, E, and H) Immunohistochemistry (IHC) for MET
protein (original magniﬁcation, 40). IHC staining of METwas performed using Anti-c-Met Antibody IHC-plus LS-B2812 (LSBio,
Seattle, WA). Black arrows indicate membrane and cytoplasmic positive staining. (C, F, and I) Hematoxylin–eosin stain
(original magniﬁcation, 10).
February 2016 Letters to the Editor e29might be predictive for targeted therapy. Indeed,
Catenacci et al.4 reported a case of durable complete
response in metastatic gastric cancer treated
with anti–MET-TKI receptor monoclonal antibody
(Onartuzumab MetMAb) in which the primary tumor
had high MET polysomy.4
Until today, the use of biological therapies in patients
with MM, such as anti-MET drugs, was performed only
in vitro—for instance, by inhibiting the MET receptor
with PHA-665752 or with Perifosine (Keryx Bio-
pharmaceuticals, New York, NY), which directly inhibits
the EGFR/MET–AKT axis.5,6
Therefore, the presence of MET gene ampliﬁcation
and polysomy associated with MET receptor over-
expression reinforces new possibilities of treatments
also in vivo. However, whether patients with MM could
beneﬁt from MET-targeted therapies remains to be
established in clinical trials.Serena Varesano, PhD
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